Neurocrine Biosciences Names Samir Siddhanti Chief Business Officer
Neurocrine Biosciences names Samir Siddhanti Chief Business Officer to lead pipeline expansion and strategic positioning of direclidine.
Neurocrine Biosciences names Samir Siddhanti Chief Business Officer to lead pipeline expansion and strategic positioning of direclidine.
Tempest Therapeutics partners with Senlang on TPST-4003 CAR-T trial using in vivo mRNA delivery for autoimmune diseases starting in...
Rectify Pharmaceuticals names Constantine Chinoporos executive chairman as RTY-406 advances through Phase 1 trials for primary sclerosing cholangitis.
Adneuris grants Cebranopadol Greater China rights to Zhejiang Conba in a $17.5M upfront deal with over $100M in milestone...
Avere Therapeutics merges with NextCure in $320M financing for oral IL-23 drug AVR-001, targeting once-weekly dosing in psoriasis and...
FDA approves Leqembi Iqlik subcutaneous injection for early Alzheimer's, enabling once-weekly self-administration at home versus infusion centers.
Rani Therapeutics expands its obesity pipeline through a new partnership with PegBio, adding multiple candidates to its RaniPill oral...
Ryoncil generates $115M in revenue 18 months after FDA approval, exceeding initial projections with strong pediatric transplant center adoption.
Teva secures global rights to Polpharma's ocrelizumab biosimilar, covering IV and subcutaneous formulations across major markets.
Chemomab and Scipher merge to advance nebokitug in RA using AI-driven patient selection and Medicare-covered diagnostic testing.